An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial).
Tracey H SachKim Suzanne ThomasJonathan M BatchelorPerways AkramJoanne R ChalmersRachel Helen HainesGarry D MeakinLelia DuleyJane C RavenscroftAndrew RogersMiriam SanterWei TanJennifer WhiteMaxine E WhittonHywel C WilliamsSeau Tak CheungHamdi HamadAndrew WrightJohn R IngramNick J LevellJonathan Mark Ruthven GouldingAreti MakrygeorgouAnthony BewleyMalobi OgboliJulia StainforthAdam FergusonBisola LagudaShyamal WahieRobert EllisJaskiran AzadAmirtha RajasekaranViktoria EleftheriadouAlan A Montgomerynull nullPublished in: The British journal of dermatology (2020)
Combination treatment, compared with TCS alone, has a lower incremental cost per additional successful treatment than NB-UVB only. Combination treatment would be considered cost-effective if decision makers are willing to pay £1932 per additional treatment success.